371 results about "Lipopolysaccharide" patented technology

The invention discloses application of scylla serrata antibacterial peptide Scycin in preparation of an anti-inflammatory composition and a preparation method of the scylla serrata antibacterial peptide Scycin. The nucleotide sequence of the scylla serrata antibacterial peptide Scycin is shown as SEQ ID NO.01. The invention further discloses a preparation method of the scylla serrata antibacterial peptide Scycin. In an LPS (lipopolysaccharide)-induced RAW 264.7 macrophage inflammation model, the recombinant expression plasmid vector containing the scylla antibacterial peptide Scin remarkably inhibits an inflammation cascade reaction by down-regulating expression of proinflammatory factors such as TNF-alpha (tumor necrosis factor-alpha) and IL-6 (interleukin-6), the anti-inflammatory effect of the recombinant expression plasmid vector is equivalent to that of a mesalazine positive control group, and obvious cytotoxicity is not observed.

The invention discloses a fish by-product active peptide, a preparation and application, and belongs to the technical field of biological active peptides. The amino acid sequences of the fish by-product active peptide are shown as SEQ ID NO: 1 to SEQ ID NO: 3. Both the single peptide fragment and the compound peptide fragment of the fish by-product active peptide can obviously inhibit NO secretion of a lipopolysaccharide (LPS)-induced macrophage (RAW264.7) inflammation model, so that the fish by-product active peptide has a relatively good application prospect in preparation of a product with an anti-inflammatory effect; and a foundation is laid for high-added-value utilization of salmon byproducts and promotion of research, development and application of functional active peptides.

The invention discloses an application of phenyllactic acid or a composition containing phenyllactic acid in preparation of medicines for relieving lung diseases, and in the application, the lung diseases are preferably pulmonary fibrosis or acute lung injury. In an acute lung injury research model, phenyllactic acid can effectively intervene in the inflammatory factor cascade reaction and oxidative stress injury process, and acute lung injury symptoms caused by the factors are remarkably improved. Compared with the traditional treatment means, the experiment proves that the phenyllactic acid or the composition containing the phenyllactic acid can obviously relieve the symptoms of acute lung injury (ALI) of mice induced by lipopolysaccharide (LPS) and pulmonary fibrosis (PF) of mice induced by bleomycin, the pathological change of the lung is effectively improved, and the lung function is recovered.

The invention provides a compound probiotic for relieving acute lung injury and application of the compound probiotic, and particularly discloses application of the compound probiotic consisting of bifidobacterium animalis YRK-12 and lactobacillus rhamnosus LRa-Y8 in preparation of a medicine for relieving the acute lung injury. Wherein the preservation number of the bifidobacterium animalis YRK-12 is CGMCC (China General Microbiological Culture Collection Center) No.28597; the preservation number of the lactobacillus rhamnosus LRa-Y8 is CGMCC (China General Microbiological Culture Collection Center) No. 34186. Experimental verification shows that the compound probiotics can remarkably relieve acute lung injury induced by lipopolysaccharide (LPS) through a synergistic effect; specifically, the weight loss rate of mice is reduced, pathological injuries of lung tissues are improved (the structural integrity of alveolar alveoli is maintained, and inflammatory cell infiltration is reduced), the levels of proinflammatory factors (IL-1beta, TNF-alpha and IL-6) in serum and lung tissues are reduced, and the level of anti-inflammatory factors (IL-4) is increased, so that the immune balance of the lung is regulated through an intestine-lung axis; and a safe and effective novel micro-ecological regulation strategy is provided for prevention and treatment of acute lung injury.

The invention discloses an alveolar macrophage glycyrrhetinic acid liposome and a preparation method thereof, and belongs to the field of biological medicines. The surface of glycyrrhetinic acid lipidosome is modified with alveolar macrophage targeting molecules, so that the lipidosome can specifically target M1 alveolar macrophages induced by lipopolysaccharide serving as a main component of the outer wall of gram-negative bacteria, entrapped glycyrrhetinic acid is ingested by the alveolar macrophages, M2 polarization is specifically induced, and the specific targeting effect is achieved. Lung inflammatory injury caused by gram-negative bacteria is reduced, lung tissue injury and fibrosis caused by excessive inflammation are prevented, and great significance is achieved for pneumonia caused by gram-negative bacteria.

The present invention discloses the preparation of an anti-inflammatory peptide derived from the hydrolysis of shell nacre protein and its application in skin repair. The peptide PDFDNGF provided by the invention can effectively promote the proliferation of RAW264.7 macrophage cells and inhibit the excessive production of nitric oxide and cytokines in RAW264.7 cells induced by lipopolysaccharide, while increasing the levels of anti-inflammatory cytokines, demonstrating significant anti-inflammatory activity. Furthermore, the active peptide has a significant proliferative effect on L929 cells, indicating its potential to promote skin wound healing. This invention provides a theoretical basis for the high-value utilization of shell nacre.

The invention discloses a preparation method and antipyretic and anti-inflammatory application of a novel carrier-free metal-organic small molecule supramolecular hydrogel derived from Maxing Shigan Decoction. The hydrogel drug raw materials of the invention include pseudoephedrine hydrochloride in Ephedra sinica in the prescription of Maxing Shigan Decoction, amygdalin in Armeniaca vulgaris, magnesium ions in Gypsum fibrosum, and glycyrrhizic acid in Glycyrrhiza uralensis Fisch. The preparation method of the quaternary magnesium hydrogel drug is simple, green, has good stability and high biocompatibility. In a rat fever model induced by lipopolysaccharide at different doses, the antipyretic effect of the hydrogel drug can last up to 12 hours, and the antipyretic effect is significantly better than that of other metal ions such as quaternary calcium hydrogel, quaternary zinc hydrogel, and quaternary copper hydrogel groups. At the same time, it has a more persistent antipyretic effect than the whole prescription of Maxing Shigan Decoction; the hydrogel drug does not require the addition of excipients, has no toxic and side effects, and has a high drug utilization rate.

The invention relates to a biomarker for screening intestinal flora transplantation donors and application of the biomarker. The biomarker comprises intestinal flora and metabolites thereof, the intestinal flora comprises phylum firmicalis, bacteroides and the like, and the metabolites comprise short-chain fatty acid, tryptophan, indole, 5-hydroxytryptamine, lipopolysaccharide and the like. According to the method, the intestinal flora of different crowds is deeply analyzed, the relationship between each related index of the intestinal flora and the intestinal flora transplantation effect is studied, sufficient clinical verification is carried out, a biomarker for screening the intestinal flora transplantation donor is excavated, and a standard for judging whether the intestinal flora transplantation donor is qualified or not is established; and a new method and a new idea are provided for efficiently and accurately screening intestinal flora transplantation donors.

A Bifidobacterium longum subsp. longum dipro-017. The Bifidobacterium longum subsp. longum dipro-017 used has the ability to metabolize tryptophan to produce indole-3-lactic acid, can inhibit the pathogenic bacteria Salmonella Typhimurium, Staphylococcus aureus, and Escherichia coli, and can effectively mitigate weight loss caused by ulcerative colitis, improve a DAI score, improve colon length, mitigate the content of lipopolysaccharide (LPS) in blood, and increase the level of anti-inflammatory cytokine IL-10, as well as mitigate the content of bone metabolism indicators tartrate-resistant acid phosphatase (TRAP) and N-terminal propeptide of type I procollagen (PINP) in blood.

The invention discloses application of sodium butyrate to prevention and treatment of dairy cow mastitis, and belongs to the technical field of biology. The invention can provide an application of sodium butyrate in preventing and treating cow mastitis, in particular an application in preparing a preparation for preventing and treating cow mastitis induced by lipopolysaccharide (LPS) in escherichia coli. According to the application of the sodium butyrate in the aspect of preventing and treating the dairy cow mastitis, expression of key factors such as mammary gland tight junction protein is up-regulated under stimulation of lipopolysaccharide (LPS), and the sodium butyrate can effectively inhibit apoptosis and enhance the barrier function of mammary gland acinus, so that the effect of preventing and treating the dairy cow mastitis is achieved.

The invention discloses application of plant-derived glyceroglycolipid in preparation of an anti-inflammatory product, inflammation is RAW264.7 cell inflammatory response induced by LPS (lipopolysaccharide), and the plant-derived glyceroglycolipid can resist inflammation by inhibiting expression of inflammatory factors. By combining column chromatography with chromatographic analysis, efficient extraction, precise separation and structural identification of the plant GL are realized, and important technical support is provided for research of plant lipids. The plant GL can significantly inhibit inflammatory response of RAW264.7 macrophages, including reduction of LPS-induced cellular morphological change, down-regulation of inflammatory factor mRNA expression and reduction of CD86 expression level. The invention provides a solid molecular level theoretical basis for the application of the plant glycerol glycolipid in the development of anti-inflammatory functional foods and medicines.

The invention provides an extraction and detection method of a day lily active matter and application of the day lily active matter in anti-neuritis. Hemerocallis fulva contains various bioactive substances including flavone, polysaccharide and saponin, and the substances have potential application value in the fields of medicines and health care products. The invention provides a method for extracting the active components step by step, and rapid identification and detection are carried out by utilizing technologies such as fluorescence and ultraviolet-visible spectrophotometry. In addition, the invention also develops a detection method for evaluating the anti-neuritis effect of the active substances. Lipopolysaccharide (LPS) is used for stimulation to establish an inflammation model, day lily active substances are added, and the active substances are found to be capable of remarkably inhibiting generation and release of inflammatory factors and promoting growth and differentiation of neurons. Scientific basis is provided for developing new neuritis treatment methods, related drugs and the like.

The invention relates to application of visceral odorobacter and outer membrane vesicles thereof in preparation of drugs for treating acute lung injury, and relates to the technical field of drugs. The modeling medicine lipopolysaccharide is applied to a mouse individual in a nasal dripping mode, the administration mode is that each mouse is administered once a day, and intragastric administration is carried out once a day after modeling is carried out for two days and lasts for 7 days. Experiments prove that visceral odorobacter and outer membrane vesicles of the visceral odorobacter reduce the number of M1 type alveolar macrophages by down-regulating proinflammatory factors IL-6, TNF-alpha and IL-1beta in lung tissues and inhibiting three proinflammatory factors IL-6, TNF-alpha and IL-1beta in serum, so that the effect of remarkably reversing acute lung injury is achieved. The visceral odor bacilli and the outer membrane vesicles thereof are used for preventing and treating the acute lung injury, and a new method and means are provided for clinically treating the acute lung injury.

The invention discloses a crocodile polypeptide with anti-inflammatory and intestinal flora regulating functions and a preparation method thereof, belongs to the technical field of functional polypeptide preparation, and particularly relates to a preparation method of the crocodile polypeptide, an anti-inflammatory effect of the crocodile polypeptide and a regulating effect of the crocodile polypeptide on intestinal flora in ulcerative colitis inflammation. According to the preparation method, the crocodile polypeptide is prepared by combining multiple physical processing with enzymolysis, so that the purity and the biological activity of the crocodile polypeptide are improved. On the basis, a lipopolysaccharide-induced THP-1 in-vitro cell inflammation model and a dextran sodium sulfate-induced mouse in-vivo ulcerative colitis inflammation model are established, and the in-vivo and in-vitro anti-inflammatory effect of the crocodile polypeptide is further researched. The crocodile polypeptide prepared by the invention has a remarkable inhibition effect on THP-1 cell inflammation induced by lipopolysaccharide. Meanwhile, the crocodile polypeptide prepared by the preparation method disclosed by the invention has an adjusting effect on intestinal flora. The food or functional food with the effects of relieving ulcerative colitis and regulating intestinal flora can be prepared.

The invention discloses a construction and evaluation method of a PM2.5 induced chronic obstructive pulmonary disease acute exacerbation mouse model, and relates to the technical field of disease animal models. The invention aims to evaluate whether PM2.5 can induce acute exacerbation of COPD through a mouse model, a COPD model is established by adopting combined treatment of smoking and lipopolysaccharide (LPS), and an infectious AECOPD model is established by using common klebsiella pneumoniae (KP) nasal drop on the basis. Meanwhile, PM2.5 processing is added on the basis of the COPD model, and the effect of PM2.5 on acute exacerbation of COPD is evaluated. Through comparison with a classical model (an infectious AECOPD model), the potential effect of PM2.5 in induction of acute exacerbation of COPD is evaluated, and an important reference is provided for future research on an AECOPD animal model induced by air pollution.

The invention belongs to the technical field of natural pharmaceutical chemistry, and discloses a benzofuran compound in dalbergia odorifera and a preparation method and application thereof.The benzofuran compound is separated from dalbergia odorifera of a leguminous dalbergia plant, the heartwood of the dalbergia odorifera is extracted and concentrated to obtain extract, and the extract is filtered to obtain the benzofuran compound. The extract is taken and sequentially subjected to silica gel column chromatography, medium-pressure ODS column chromatography and gel column chromatography separation for multiple times, then semi-preparative high performance liquid chromatography is used for purification, and the benzofuran compounds can be obtained. According to the present invention, lipopolysaccharide (LPS) is adopted to induce RAW 264.7 cells to establish an inflammation model, such that the compound has good anti-inflammatory activity, IC50 is 14.33 [mu] M, and expression of inflammatory factor interleukin-6 (IL-6) and interleukin-1 [beta] (IL-1 [beta]) can be inhibited;

The use of 2'-fucosyllactose in the preparation of a food / drug for promoting intestinal glycocalyx development and preventing intestinal glycocalyx damage caused by lipopolysaccharide (LPS). The use of 2'-fucosyllactose in the preparation of a food / drug for the adjuvant treatment and / or adjuvant prevention of gastrointestinal infections, inflammatory bowel diseases, obesity or allergy caused by glycocalyx damage. Before adherent growth of Caco-2 cells, adding 2'-FL for co-culture with the Caco-2 cells can simulate the intestinal growth and maturation state. In the state, 2'-FL can significantly promote the development of the glycocalyx layer of Caco-2 cells, and can further prevent the glycocalyx layer damage caused by LPS on this basis.

The invention belongs to the technical field of genetic engineering, and particularly relates to application of miRNA related to cow mastitis. The invention provides an application of miR-320b in preparation of a medicine for treating dairy cow mastitis, the nucleotide sequence of the miR-320b is shown as SEQ ID NO.1, and the miR-320b is used for diagnosing the process of resisting Escherichia coli, E. coli type dairy cow mastitis. The miR-320b expression quantity of the miR-320b in the dairy cow mammary epithelial cells or E. coli type mammary tissue induced by lipopolysaccharide (LPS) is detected, and when the expression quantity of the miR-320b is obviously reduced, the miR-320b is prompted to have an anti-inflammatory function in the dairy cow mastitis.

The present invention belongs to the field of agarwood, and in particular to a kind of 2-(2-phenylethyl) chromone and lignan heterocompound and its application. The present invention uses the agarwood produced by thick-leaved agarwood tree as raw material, and after reflux extraction, successively adopts silica gel, Sephadex LH-20 gel, high performance liquid chromatography and other chromatographic techniques to separate and purify to obtain 1 monomer compound, and its structure is identified by spectral methods such as mass spectrometry and nuclear magnetic resonance and combined with physicochemical properties. It is retrieved as a new compound by SciFinder and named as thick-leaved agarwood alcohol (aquicrassnol), which is the first heterocompound formed by 2-(2-phenylethyl) chromone and lignan found in agarwood. It has been verified by experiment that the compound has an inhibitory effect on the production of nitric oxide in mouse mononuclear macrophage RAW264.7 induced by lipopolysaccharide, and its half-maximal inhibitory concentration value is 47.53±2.14μmol / L, which has anti-inflammatory activity.

The application belongs to the technical field of natural medicinal chemistry, and discloses a benzofuran compound in Jinyunming and a preparation method and application thereof. The benzofuran compound is separated from Jinyunming of the plant Dalbergia hupeana Tutch in the family of Leguminosae. The heartwood of Jinyunming is extracted and concentrated to obtain extract, the extract is sequentially separated by multiple silica gel column chromatography, medium-pressure ODS column chromatography and gel column chromatography, and then purified by semi-preparative high-performance liquid chromatography, so that the benzofuran compound can be obtained. The application establishes an inflammation model by inducing RAW 264.7 cells with lipopolysaccharide (LPS), and shows that the compound has good anti-inflammatory activity, the IC50 is 14.33 μM, and the expression of inflammatory factors interleukin-6 (IL-6) and interleukin-1β (IL-1β) can be inhibited.

Disclosed are a metal-polyphenol nano-coating-wrapped tumor whole cell, a preparation method therefor, and use thereof. A plant polyphenol in the present invention and manganese ions can be rapidly assembled at room temperature to form a dense coating on the membrane of a tumor cell. The nano-coating wrapping inactivates the tumor cell, ensuring that the vaccine is safe. The nano-coating can prevent any potential tumor antigen from being lost under physiological conditions. The nano-coating is further modified with a lipopolysaccharide, which can promote the endocytosis of the formed whole-cell vaccine by antigen-presenting cells. While forming the structural coating, ions of the metal manganese can stimulate the STING pathway to enhance the anti-tumor effect.

The invention belongs to the technical field of biological detection, and particularly relates to a preparation method of lipopolysaccharide-beta-1, 3-glucan binding protein and application of the lipopolysaccharide-beta-1, 3-glucan binding protein in preparation of a broad-spectrum colloidal gold detection product for dermatophytes. The prokaryotic expression system induces the procambarus clarkii-sourced lipopolysaccharide-beta-1, 3-glucan binding protein to be efficiently expressed in an inclusion body form, the optimized inclusion body purification-renaturation process is combined to realize batch preparation, and the colloidal gold chromatography technology is integrated, so that the procambarus clarkii-sourced lipopolysaccharide-beta-1, 3-glucan binding protein is obtained. The bottlenecks of the traditional detection method in sensitivity, broad spectrum and field applicability are broken through.

The invention discloses application of a cyclic peptide compound BIM 23042 or a preparation thereof in preparation of medicines for treating bacterial infectious diseases, and belongs to the technical field of medicines. The invention discloses a cyclic peptide compound BIM 23042 as an antibiotic synergist for the first time, and the cyclic peptide compound BIM 23042 is used for treating bacterial infectious diseases. According to the application disclosed by the invention, the cyclopeptide compound BIM 23042 and polymyxin are combined for use, so that the growth of gram-negative bacteria can be effectively and synergistically inhibited. The combined medication scheme shows a remarkable advantage in coping with acinetobacter baumannii. The cyclic peptide compound BIM 23042 disclosed by the invention has an anti-infection capability, and the anti-infection capability is specifically shown as reducing the inflammatory response of macrophage RAW 264.7 induced by LPS (Lipopolysaccharide) and also reducing the apoptosis of the macrophage RAW 264.7 caused by the LPS. The invention provides a new perspective for developing a novel drug-resistant gram-negative bacterium prevention and control strategy, and also provides a new treatment scheme for coping with bacterial infection.

It is considered that diabetes-associated dementia is mainly caused by insulin resistance and relative insulin deficiency in the brain. Delivery of drugs to the brain is inhibited by the blood-brain barrier, and therefore, there has been so far no drug that provides excellent drug delivery to the brain. Therefore, there has been no wonder drug for diabetes-associated dementia. LPSs have a high molecular weight and therefore do not pass through the blood-brain barrier. It is possible to provide a composition for a drug, food, or the like that has the effect of preventing and treating impairment due to diabetes-associated dementia, by means of a lipopolysaccharide derived from a bacterium belonging to the genus Pantoea. A lipopolysaccharide derived from a bacterium belonging to the family Enterobacteriaceae is confirmed to be safe when used for oral or transdermal administration in the form of food, cosmetics, feed, or the like, and thus can be expected to provide prophylactic and therapeutic effects with a low risk of side effects.

The invention relates to biomedical engineering, and discloses a biochip screening method of a therapeutic agent based on intestinal brain axis regulation and application thereof. The screening method comprises the following steps: performing intestinal wall cell culture or microglial cell culture by adopting a metasurface plasmon resonance biochip of which the surface is subjected to bionic treatment to obtain an intestinal wall cell adherent chip board or a microglial cell adherent chip board; the method comprises the following steps: adding a culture medium containing a chemotherapeutic drug or lipopolysaccharide into a cell-adherent chip board for culture I, then removing the culture medium, adding a therapeutic agent to be detected for culture II to obtain a culture solution, and detecting the cell repair effect of intestinal wall cells or microglial cells in the culture solution, and screening to obtain a therapeutic agent with a repairing effect on intestinal wall cells and / or microglial cells. The screening method can be used for efficiently and accurately screening the therapeutic agent with dual effects of intestinal regulation and neuroprotection from a plurality of therapeutic agents to be detected, and can be used for dynamically monitoring and exploring the interaction condition of the therapeutic agent and cells on line in an unmarked and real-time manner.

The invention relates to saxifraga stolonifera polysaccharide and application thereof in preparation of complement inhibitors or anti-inflammatory drugs. Based on activity guidance, it is found that a water extraction part of saxifraga stolonifera has good anti-complement activity when experimental screening is conducted on the anti-complement active part of saxifraga stolonifera, graded alcohol precipitation is conducted on the water extraction part, the activity of crude polysaccharide precipitated by 90 alcohol (90% ethyl alcohol) is higher than that of crude polysaccharide precipitated by 75 alcohol (75% ethyl alcohol), and the anti-complement activity of the crude polysaccharide precipitated by 90 alcohol is higher than that of a positive drug (heparin). On the basis, five neutral heteropolysaccharides with anticomplement activity, namely SSP-90-1, SSP-90-2, SSP-90-3, SSP-90-4 or SSP-90-5, are separated from the 90 alcohol precipitation crude polysaccharide. Compared with the prior art, the structural characteristics of the saxifraga stolonifera polysaccharide are represented, and the preparation method of the saxifraga stolonifera polysaccharide and the application of the saxifraga stolonifera polysaccharide in preparation of complement inhibitors and anti-inflammatory drugs are provided. The invention verifies the anti-complement activity of the saxifraga stolonifera polysaccharide and the therapeutic effect of the saxifraga stolonifera polysaccharide on lipopolysaccharide (LPS)-induced acute lung injury and systemic inflammatory response.

The present application provides an activity analysis detection method for a stress-induced mesenchymal stem cell extract, comprising step one, culturing human primary articular chondrocytes; step two, aspirating the culture fluid, adding an equal volume of a composition to be tested, and incubating, wherein the composition to be tested includes a mesenchymal stem cell extract; step three, then adding an equal volume of a lipopolysaccharide solution with a concentration of 80ng / mL-120ng / mL, continuing to incubate, and collecting a cell lysate, which is used to detect inflammatory cytokines. The present application determines the optimal use concentration and cell incubation time of a mesenchymal stem cell extract (denoted as Alituo) and a lyophilized composition (denoted as Alip) and a lipopolysaccharide solution by measuring cell viability and the levels of inflammatory factors IL-6, IL-1β, and TNF-α. By detecting cell viability and inflammatory factors, the quality of the mesenchymal stem cell extract can be efficiently evaluated, and the activity analysis detection method has high repeatability and good stability.

The invention belongs to the technical field of natural pharmaceutical chemistry, and discloses a flavonoid compound in lomatogonium radiatum as well as a preparation method and application thereof.The flavonoid compound is separated from lomatogonium radiatum of a gentiaceae lomatogonium plant, the medicinal material of lomatogonium radiatum is extracted and concentrated, and the flavonoid compound is obtained. And sequentially carrying out macroporous adsorption resin separation, gel column chromatography separation, medium-low pressure ODS column chromatography separation and semi-preparative high performance liquid chromatography separation. Pharmacological studies show that the compound provided by the invention can effectively inhibit the levels of COX2, IL-6 and TNF-alpha in mouse macrophages RAW246.7 caused by lipopolysaccharide (LPS), which indicates that the compound has obvious anti-inflammatory activity and can be used for preparing anti-inflammatory drugs.

The present application belongs to the field of microbial culture, and particularly relates to a culture medium for reducing expression of surface polysaccharide of Vibrio parahaemolyticus. The formula of the polysaccharide low-expression culture medium is selected from specific proportion of nutritional components and specific conditions for inhibiting polysaccharide expression, so that the expression amount of surface lipopolysaccharide and capsule polysaccharide of Vibrio parahaemolyticus after the culture medium is increased is lower than the expression amount of polysaccharide of Vibrio parahaemolyticus after normal culture, the expression of surface lipopolysaccharide and capsule polysaccharide can be inhibited to a certain extent, the surface of the bacterial body can better expose outer membrane protein, and the immunodetection of Vibrio parahaemolyticus is facilitated. The present application provides a technical basis for developing a complete immunodetection method of Vibrio parahaemolyticus.

This invention discloses a hydrogel for tumor treatment based on improving the tumor microenvironment to trigger gas therapy combined with chemotherapy, belonging to the field of biomedical technology. The hydrogel drug delivery system utilizes lipopolysaccharide (LPS) to induce local inflammatory stimulation, thereby altering the tumor microenvironment of breast cancer and promoting nitric oxide (NO) production. The NO donor arginine (L-Arg) and the chemotherapy drug doxorubicin (DOX) are transported using sodium alginate (ALG), achieving combined gas therapy and chemotherapy to inhibit breast tumor growth. The drug delivery system of this invention not only enhances the effect of chemotherapy but also simultaneously achieves precise drug delivery and reduces drug dosage. The preparation method of the drug delivery system of this invention is simple, safe, and without toxic side effects, showing promising application prospects in tumor treatment and possessing significant clinical value.